Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07259473

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma (Pre-CATALIS)

Factors Influencing Immunotherapy Response in Mismatch Repair Deficiency (dMMR) / Microsatellite Instability-High (MSI-H) Gastric/Gastroesophageal Junction Adenocarcinoma

Sponsor: Shanghai Zhongshan Hospital

Conditions Gastric / Gastroesophageal Junction Adenocarcinoma Immunotherapy Mismatch Repair Deficient or MSI-High Solid Tumors

Interventions D2 radical gastrectomy Immunotherapy Induction chemotherapy

Updated 2 times since 2026 Last updated: Jan 2, 2026 Started: Jan 31, 2026 Primary completion: Dec 30, 2029 Completion: Dec 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric / Gastroesophageal Junction Adenocarcinoma and Immunotherapy, this trial is actively recruiting participants. The trial is conducted by Shanghai Zhongshan Hospital and has accumulated 2 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE2

Phase: None → PHASE2
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Zhongshan Hospital

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.